Background: Recombinant factor VIIa (rFVIIa), a hemostatic agent approved for hemophilia, is increasingly used for off-label indications.
R
ecombinant factor VIIa (rFVIIa) is an expensive and potent procoagulant. The U.S. Food and Drug Administration (FDA) approved intravenous use of rFVIIa in 1999 for patients with hemophilia A or B and antibody inhibitors against standard-factor replacements. Recently, its use has expanded beyond these approved indications to encompass a wide range of in-hospital, off-label applications.
Off-label drug use refers to any application that deviates from FDA-approved use. The FDA drug-approval process mandates that randomized, clinical trials demonstrate efficacy and safety. Once approval is given, however, physicians are free to use the drug for other indications. Although off-label use is legal and allows for rapid adoption of some therapies, the available evidence supporting it usually falls short of the rigor that accompanies FDA review. Even though the resulting uncertainty may be acceptable, concerns increase when off-label use is applied to conditions that are clinically distinct from approved indications or it is done frequently, is costly, or is associated with important side effects or harms.
The off-label use of rFVIIa for hospitalized patients has increased, despite concerns about efficacy and safety, including evidence suggesting an increased rate of thromboembolic events (1) (2) (3) (4) (5) . Our comparative effectiveness review evaluates the benefits and harms of in-hospital, offlabel use of rFVIIa in adults for the selected indications of intracranial hemorrhage (ICH), cardiac surgery, trauma, liver transplantation, and prostatectomy.
METHODS
The Agency for Healthcare Research and Quality (AHRQ) commissioned the full report, which is available, including the search strategies and detailed evidence tables, at the AHRQ Web site (6) . We developed and followed standardized protocols for data searches, extraction, quality assessments, and syntheses.
Data Sources and Searches

Searches
In collaboration with a research librarian, we developed individualized search strategies for 10 bibliographic databases from inception through 31 December 2010: PubMed, EMBASE, the Cochrane Library, ACP Journal Club, Database of Abstracts of Reviews of Effects, Cochrane Central Register of Controlled Trials, CMR, Health Technology Assessment, National Health Service Economic Evaluation Database, and BIOSIS. We contacted experts and reviewed bibliographies of identified systematic reviews, files supplied by the manufacturer, and the manufacturer's Web site. A librarian expert on gray literature (sources other than published materials indexed in bibliographic databases) searched regulatory sites, clinical trial registries, conference proceedings, and grant-funded and federally funded research sites and contacted authors of abstracts to determine whether full reports had been subsequently published.
Inclusion Criteria
We sought studies that compared the use of rFVIIa with alternative therapies, placebo, or usual care for hospitalized patients with 5 off-label indications: ICH, cardiac surgery, trauma, liver transplantation, and prostatectomy. For inclusion, studies had to address direct or surrogate clinical outcomes. We did not contact authors about results that were not reported in their publications. We excluded studies published only as abstracts and studies of human factor VIIa or modified recombinant forms under development; studies on use of rFVIIa for on-label indications and rFVIIa applied to patients substantially similar to those for whom on-label indications are approved (for example, Glanzmann thrombasthenia); and studies whose outcome measures (for example, drug half-life) are not relevant to efficacy, effectiveness, or safety. Lastly, we reviewed the English-language abstracts and references of studies published in non-English languages. Among these, we identified 2 small comparative studies likely eligible for effectiveness review (randomized, controlled trial [RCT] of cardiac surgery [11 patients who received rFVIIa] [7] and comparative cohort study of brain trauma [7 who received rFVIIa] [8] ) and 6 case series reports (range, 16 to 35 patients) (9 -14) likely eligible for harms analyses if we had the capacity to do a full-text review. The RCT was used for sensitivity testing, with similar results to those reported here. The other articles not published in English were excluded from further review on the basis of a lack of capacity for translation and the determination that such exclusions were unlikely to bias our findings because few articles were identified and the studies enrolled few patients.
Study Selection
Two reviewers independently screened titles and abstracts to identify clinical use of rFVIIa for the selected indications and identified all RCTs and observational studies for full-text review. For the effectiveness analyses, we included RCTs and comparative observational studies. We reviewed all RCTs in detail, whereas we reviewed only comparative observational studies of fair or good quality in detail. We used comparative observational studies of poor quality for qualitative sensitivity analyses. Patients from overlapping or duplicate articles reporting on the same patient population were included only once.
Although noncomparative studies are a less reliable source of evidence than comparative studies, they may report infrequent events not identified in RCTs (15) . Given concerns about the possibility of clinically significant harms, we included registries and cohorts with at least 15 total patients in the harms analyses. We selected 15 patients as the minimum threshold because the risk for bias (for example, selective reporting) is probably increased in smaller reports. We also included the treatment groups of all comparative studies in the harms analyses.
Data Extraction and Quality Assessment
Two reviewers independently rated study quality and indication-wide strength of evidence and abstracted study characteristics by using pretested electronic forms. Study quality and indication-wide strength of evidence were evaluated by using well-established criteria (16 -25) and a predefined systematic approach described further in the AHRQ report (6) . The quality criteria were specific to the study type and were used to assign each study a quality score from the ordinal scale of poor, fair, or good by using qualitative determinations rather than numerical scores. For RCTs, essential quality elements included appropriate randomization, allocation concealment, blinding, and absence of differential follow-up. For observational studies, essential quality elements included appropriate methods to generate comparability of groups and control for confounding, appropriate blinding, and absence of differential follow-up. Studies that did not achieve (or did not adequately report) these elements were assigned a quality score of poor. Studies that achieved these partially or fully were felt to have a lower risk for bias and were assigned quality scores of fair or good, respectively. Strength of evidence (low, moderate, high, or insufficient) was determined similarly (17) . Five types of data were abstracted from each included study: study design, population evaluated, rFVIIa dosing and administration, outcomes assessed, and study funding. Disagreements were resolved by discussion and, when necessary, review by a third author.
Data Synthesis and Analysis
We summarized mortality, thromboembolism, and other outcome rates for included studies. We considered studies eligible for meta-analysis if they were good-or fairquality RCTs or good-quality observational studies and had similar interventions and patient populations. We did meta-analyses when there were at least 2 studies of fair or better quality, including at least 1 of good quality.
The ICH RCTs had several intervention groups in which varying doses of rFVIIa were compared with a single control group. For these, we used a least-square fixedeffects model, a standard meta-analytic methodology for synthesizing studies of this design (see the Gleser-Olkin model [26 -28] ). We did meta-analyses by using both fixed-effects and random-effects models for sensitivity testing. We calculated standardized mean differences for percentage of hematoma expansion, the only continuous variable analyzed. For dichotomous outcomes, we calculated 2 effect-size metrics: risk differences (RDs) and arcsine standardized mean differences (29) . Results from these metrics were consistent. For ease of interpretation and because outcome rates were similar across studies (such that disadvantages of the RD metric were minimized), only RDs are reported here. We did meta-analytic calculations with the R statistics package, version 2.11.1 (www.r-project.org), by using a modified meta package (Guido Schwarzer, sc@imbi .uni-freiburg.de, version 1.6-0). Although we did assessments of heterogeneity by using the Q and I 2 statistics, we expected these to be nonsignificant if too few studies were included in each meta-analytic calculation. In that case, differences in findings between the fixed-and randomeffects analyses were expected to highlight the presence of heterogeneity.
Because the literature suggested a dose-response relationship between rFVIIa and certain outcomes, particularly arterial thromboembolism, and the ICH RCTs reported outcomes separately for several rFVIIa doses and arterial versus venous thromboemboli, we chose a priori to analyze these data according to low, medium, and high doses (Յ40 mcg/kg, Ͼ40 but Ͻ120 mcg/kg, and Ն120 mcg/kg) and arterial versus venous thromboembolic outcomes. Doseresponse analyses were not possible for other indications because there were too few patients at specific dosages, dosages were unclear, or outcomes were not reported by dosage.
Role of the Funding Source
Primary funding for the project was provided by the AHRQ, with additional support from the National Heart, Lung, and Blood Institute and the Palo Alto Medical Foundation Research Institute. Although the AHRQ formulated the initial study questions, the funding sources otherwise had no role in the design and conduct of this study or in the collection, management, analysis, or interpretation of the data. The AHRQ reviewed the manuscript but did not assist in its preparation. The funding sources had no role in the decision to submit the manuscript for publication.
RESULTS
Our searches identified 6191 potentially relevant articles, of which 62 articles reporting on 64 studies met inclusion criteria (Appendix Figure, available 91] observational studies) were included in the harms analyses. Overall, no studies compared rFVIIa with predecessor products that might be considered alternatives for some indications (for example, activated prothrombin complex concentrates). Instead, the RCTs examined rFVIIa versus placebo and the comparative observational studies compared it with usual care. There were few fair-or goodquality studies within any indication (Table) (6) . Randomized, controlled trials were generally of better quality than comparative observational studies: Only 13% (2 of 16) of RCTs (41, 42) were of poor quality, whereas 62% (16 of 26) of the comparative observational studies (54 -69) were of poor quality. All observational studies that were determined to be of poor quality lacked appropriate methods to generate comparability of groups or control for confounding. The small number of studies for any given indication precluded the use of funnel plots or other approaches for evaluation of publication bias. The manufacturer of rFVIIa, Novo Nordisk (Bagsvaerd, Denmark), sponsored most of the RCTs.
Effectiveness Review Outcomes
The Table summarizes the key characteristics of the studies providing comparative effectiveness outcome data, along with their quality, strength of evidence, and conclusions. Although Figure 1 summarizes the mortality and thromboembolic event risk differences in the individual studies, few of these studies were powered to distinguish important differences between treatment groups for these direct end points. Instead, they used indirect end points (for example, transfusion requirements) as primary outcomes. For all indications, qualitative sensitivity analyses suggest that poor-quality comparative observational studies (those not reviewed in depth in the effectiveness review but included in the harms analysis [Appendix Tables 1 to 12, available at www.annals.org]) had results consistent with those reported for each indication for the RCTs and higherquality observational studies (6) . In the sections that follow, we present the benefits and harms associated with use of rVIIa by specific indication. In all cases in which meta-analyses were done, the results of the fixedeffects and random-effects models were virtually identical and were in agreement on all determinations of significant versus nonsignificant findings (that is, those that crossed the null), indicating the presence of little heterogeneity among included studies. We report results from the fixed-effects models. Unless otherwise noted, the low strength of evidence critically limits our ability to draw conclusions about the comparative effectiveness of rFVIIa and usual care.
Usual
ICH
Identified RCTs examined only intracerebral hemorrhage, rather than other forms of ICH (for example, subdural hematoma). Four RCTs (30 -33) and 1 comparative observational study (44) examined the use of rFVIIa in 968 intervention patients (Table) . Notably, although the RCTs excluded patients receiving oral anticoagulation, all of the patients in the 1 comparative observational study that met inclusion criteria were receiving oral anticoagulants-half of whom had intracerebral hemorrhage and the other half had subdural hematoma. The meta-analyses found no evidence of effect on mortality of rFVIIa at any dosing level (Figure 2 . On statistical testing, there was no evidence of dose effect for any end point, including mortality and arterial thromboembolism (6) . Thus, moderate strength of evidence suggests that the use of rFVIIa for patients with ICH who were not receiving oral anticoagulation yields no significant benefit for mortality or functional outcome but is associated with an increased risk for arterial thromboembolism.
Cardiac Surgery
Two RCTs (34, 35) and 4 comparative observational studies (45-48) of 251 adult cardiac surgery patients receiving rFVIIa met inclusion criteria, of which the 2 RCTs and 2 of the observational studies (45, 46) were of sufficient quality for meta-analysis. One RCT assessed prophylactic rFVIIa use at the conclusion of complex, noncoronary artery bypass grafting surgeries (34); the other studies evaluated treatment for postoperative bleeding. However, the timing and context of rFVIIa administration was similar for all studies because bleeding is common after complex, noncoronary artery bypass grafting surgery, and rFVIIa was given after cardiopulmonary bypass in all cases. Thus, we considered it appropriate to combine these studies. In meta-analyses, we found no effect of rFVIIa on mortality compared with usual care but an increased risk for thromboembolism (Figures 2 and 3 and Appendix Table 4). Red blood cell transfusion requirements were possibly reduced with rFVIIa, but the trend was apparent only across higher-quality studies (Appendix Table 5 ). Results about length of stay in the intensive care unit were not consistent. In summary, current evidence of moderate strength (for thromboembolic events) or low strength (for all other outcomes) suggests no mortality benefit, but that rFVIIa use increases the risk for thromboembolism. . Each circle represents a study. Larger circles correspond to larger studies, shaded circles represent studies on treatment use of rFVIIa, and open circles represent studies on prophylactic use of rFVIIa. Intracranial hemorrhage outcomes here reflect total TE events in contrast to the arterial TE events assessed in the metaanalyses. For cardiac surgery, 3 study circles overlap at the 0 abscissa for mortality risk, and 2 similarly overlap for TE event risk. ICH ϭ intracranial hemorrhage; rFVIIa ϭ recombinant factor VIIa; TE ϭ thromboembolic.
Body Trauma
Four RCTs (published in 2 articles that both report on 1 blunt and 1 penetrating trauma trial) (36, 37) and 3 comparative observational studies (49 -51) assessed 746 patients who received rFVIIa. Two RCTs (36) censored patients who died within 48 hours of injury for analyses of transfusion requirements-a critical limitation of this literature-but report on the end points of mortality, thromboembolic events, and the acute respiratory distress syndrome (ARDS) in all patients. In meta-analyses of the 4 RCTs, we found no effect of rFVIIa on mortality or thromboembolism but a significant reduction in ARDS (Figures 2 and 3 and Appendix Table 6 ). Use of rFVIIa reduced transfusion requirements in all 4 RCTs when all patients were included in the analysis (that is, including previously censored patients), but the decrease was significant in only 1 RCT (37) (Appendix Table 7 ). The observational studies did not report usable comparative data on this outcome. Overall, available evidence of moderate strength identifies no increased risk for thromboembolic events, a reduced risk for ARDS, and no difference in mortality.
Brain Trauma
One RCT (38) and 1 comparative observational study (52) evaluated 79 patients who had traumatic brain injury and received rFVIIa. The observational study included patients receiving oral anticoagulation, whereas the RCT excluded them and also patients for whom neurosurgery was planned. On systematic review, we found no effect of rFVIIa on mortality or thromboembolic events (RD [rFVIIa minus usual care] for mortality, 0 in the RCT and Ϫ0.2 in the observational study; RD for thromboembolic events, 0.07 and 0.05, respectively) ( Figure 1 and Appendix Table 8 ). In addition, rFVIIa use did not influence For ICH, all studies are RCTs (30 -33) and meta-analyses are done according to dosing category (low, medium, and high). For cardiac surgery, the studies by Diprose and colleagues (34) and Gill and coworkers (35) are RCTs, whereas those by Karkouti and colleagues (45) and Gelsomino and coworkers (46) are observational studies. For body trauma, all studies are RCTs (36, 37). ICH ϭ intracranial hemorrhage; RCT ϭ randomized, controlled trial; RD ϭ risk difference; rFVIIa ϭ recombinant factor VIIa.
hematoma growth but was associated with a reduction in time to neurosurgical intervention (that is, by more quickly normalizing the international normalized ratio) in the observational study, the 1 study that evaluated this outcome. In summary, current evidence of low strength is too limited to compare the harms and benefits of rFVIIa.
Liver Transplantation
Four RCTs (39 -42) and 1 comparative observational study (53) evaluated 215 patients with Child class B or C cirrhosis who received prophylactic rFVIIa on initiation of liver transplantation. On systematic review, we found no effect of rFVIIa on mortality or thromboembolism (RD range [rFVIIa minus usual care] for mortality, 0 to 0.01; RD range for thromboembolic events, Ϫ0.03 to 0.17) (Figure 1 and Appendix Table 9 ). There was a trend across studies toward reduced red blood cell transfusion requirements with prophylaxis, but neither operating room time nor length of stay in the intensive care unit was reduced (Appendix Table 10 ). Thus, available evidence of low For ICH, all studies are RCTs (30 -33), meta-analyses are done according to dosing category (low, medium, and high), and analyses of thromboembolic events are for arterial events only. For cardiac surgery, the studies by Diprose and colleagues (34) and Gill and coworkers (35) are RCTs, whereas those by Karkouti and colleagues (45) and Gelsomino and coworkers (46) are observational studies, and the meta-analyses of thromboembolic events evaluate all events (both arterial and venous). For body trauma, all studies are RCTs (36, 37), and the meta-analyses of thromboembolic events evaluate all events. ICH ϭ intracranial hemorrhage; RCT ϭ randomized, controlled trial; RD ϭ risk difference; rFVIIa ϭ recombinant factor VIIa.
strength is too limited to compare the harms and benefits of rFVIIa.
Prostatectomy
There was 1 RCT on prophylactic use of rFVIIa in 24 patients having retropubic prostatectomy for prostate cancer or benign prostatic hypertrophy (92) (providing an insufficient strength of evidence for all outcomes). Mortality and thromboembolic events could not be evaluated because of limited events (0 deaths, 1 thromboembolic event) (Appendix Table 11 ). Red blood cell transfusion requirements and operating room time were significantly decreased with rFVIIa use (Appendix Table 12 ).
Evaluation of Harms: Data From RCTs Versus Comparative and Noncomparative Observational Studies
Unadjusted mortality rates among patients who received rFVIIa ranged widely from 0 to 0.87 (median, 0.17), and thromboembolism rates ranged from 0 to 0.39 (median, 0.09) (6) . In general, mortality rates were lowest in RCTs and highest in observational studies, but the relationship between study type and thromboembolism rate was less clear (Figure 4) . Randomized, controlled trials of ICH-which had the longest follow-up and most completely described ascertainment of harms-had mortality and thrombembolic event rates only slightly different from those in observational studies. The discrepancy between harms reported in RCTs versus observational studies was greater for other indications. There was no apparent correlation between rFVIIa dose and harms outcomes (6), which is similar to our effectiveness review finding for ICH of no dose effect. There also was no apparent relationship between age and harms outcomes (6), although it is notable that ages tended to cluster for a given indication, which may have made any relationship difficult to ascertain. Finally, there was no observable pattern between the likelihood of mortality and thromboembolism (6) , which is similar to the effectiveness review findings for certain indications (ICH and cardiac surgery) of no effect of rFVIIa on mortality, despite an associated increase in thromboembolic events.
DISCUSSION
Available evidence indicates that in-hospital, off-label use of rFVIIa does not reduce mortality for any indication we evaluated. In contrast, use of rFVIIa increases the rate of thromboembolic events in ICH and cardiac surgery. Of the indications studied, the benefit-risk ratio may be most favorable for body trauma because rFVIIa use in this pop- , regardless of quality. For liver transplantation, the reported RCT rate of TE events is an underestimate, because 1 RCT (40) did not report venous events by group (treatment vs. placebo), so the events could not be tallied. For studies with overlapping data sets (e.g., the same registry patients being evaluated in a noncomparative study and a comparative observational study), the most complete data set for the outcome of interest was used. Comp Obs ϭ comparative observational study; ICH ϭ intracranial hemorrhage; Noncomp Obs ϭ noncomparative observational study; RCT ϭ randomized, controlled trial; TE ϭ thromboembolic.
ulation is associated with a reduced risk for ARDS, although this finding must be placed in the context of no accompanying reduction in mortality. In addition, the strength of evidence is low or moderate for all outcomes, which precludes definitive conclusions. The harms analyses raise additional concerns by noting that mortality rates among patients receiving rFVIIa are generally greater in observational studies-in which patient groups more closely reflect unselected patient populations-compared with RCTs. Our analysis of data from nonfederal U.S. hospitals found that 97% of in-hospital use of rFVIIa was off-label, with most for ICH, cardiac surgery, and trauma indications (93) . This increasingly frequent off-label use of rFVIIa is occurring despite its expense (at least $10 000 for a single 90-mcg/kg dose in a patient weighing 70 kg) (94), lack of mortality benefit, and growing evidence of associated harms. Our systematic review in some cases extends the findings of previous reviews by incorporating data from comparative observational studies in the effectiveness review, assessing the effect of dosing level when possible and assessing harms across different study types known to have varying degrees of generalizability to real-world populations. We are able to provide indication-specific findings for disparate clinical applications, as well as an overview of use that identifies outcome patterns across indications, such as an increase in thromboembolism for some. Previous reviews that pooled data for several indications identified no mortality benefit with off-label rFVIIa use (2, 95-100), and many reviews noted a nonsignificant increase in thromboembolism (2, 96) (98 -100) or, more recently, a significant increase (5), but none could provide indicationspecific guidance. Regarding specific indications, a Cochrane review of ICH and hemostatic drug therapies, overwhelmingly rFVIIa, noted no mortality reduction but a nonsignificant increase in thromboembolism (3), whereas a more recent review by Yuan and colleagues (101) had the same findings as ours regarding a significantly increased risk for arterial thromboembolism without any attendant benefits for mortality or functional outcome. A metaanalysis of cardiac surgery observed no effect on mortality and a nonsignificant increase in perioperative stroke (4). For body trauma, 3 systematic reviews concluded that rFVIIa did not decrease mortality (102) (103) (104) . For brain trauma, a recent Cochrane review by Perel and coworkers (105) identified few studies and no mortality benefit. Other reviews were more supportive of rFVIIa, describing it as a "promising" therapy (106) or one that might reasonably be used as rescue therapy (107, 108) but did not do meta-analyses. Specific to harms analyses, O'Connell and colleagues (1) evaluated data from the FDA's Adverse Event Reporting System to document serious thromboembolic events after off-label rFVIIa use.
Our analysis has several limitations. First, the heterogeneity of included studies prevented us from pooling data across clinical indications. Second, we found no studies comparing rFVIIa with predecessor products, only with placebo or usual care. Comparisons with usual care may be particularly susceptible to bias from site-to-site variations or advances in clinical care over time. Third, we excluded articles not published in English, albeit only 2 were comparative studies with very few patients. Fourth, we used quality criteria to determine which observational studies were assessed in detail in the effectiveness review, such that others may have come to different determinations. Nonetheless, these criteria were applied systematically, and qualitative sensitivity testing found that the poor-quality studies had similar findings to their better-quality counterparts. Fifth, in 2 of the body trauma RCTs (36), patients who had been enrolled under protocols with emergency exceptions to informed consent withdrew consent. Because no information was provided on their treatment groups, we were unable to assess for differential withdrawal. Sixth, the manufacturer of rFVIIa, Novo Nordisk, played a substantial role in sponsoring, designing, directing, analyzing, and publishing much of the RCT evidence. Although this circumstance might be expected and does not equate with biased research, it does require special care in evaluating the possibility of bias. Next, we cannot exclude the possibility of selective reporting or publication bias, because the small number of available studies prevents their formal assessments (for example, by using funnel plots). Finally, we found that available studies used usual care as the comparator and relied heavily on indirect outcomes, both of which may yield more favorable findings than other design options, such as those that use an active comparator or direct outcomes.
In conclusion, off-label use of rFVIIa for ICH and cardiac surgery does not reduce mortality but does increase the risk for thromboembolism. For body trauma, there was no increased risk for thromboembolism and a reduced risk for ARDS but no difference in mortality. For the remaining indications, the available evidence was too limited to do meta-analyses. Thus, limited evidence on off-label rFVIIa use for 5 indications detects no mortality benefit but does detect an increase in thromboembolism for some indications. 68 ( Studies did not meet inclusion criteria for detailed review in the comparative effectiveness analyses owing to poor quality were included in the qualitative sensitivity analyses described in the Effectiveness Review Outcomes section and the Evaluation of Harms section. ¶ Mean dose in mg rather than mcg/kg of body weight. ** Brody et al (55) report a median (range) Glasgow Coma Scale score at discharge by group (15 ϭ normal, 0 ϭ dead): rFVIIa, 13.5 (13) (14) (15) and usual care, 15 (13) (14) (15) 68 ( (33) is smaller than reported for mortality and poor modified Rankin scale score because thromboembolic event rates were calculated on the basis of the "safety population"
(i.e., patients exposed to a study agent) rather than the patients who were randomly assigned. † Thromboembolic event rates were calculated by dividing the number of thromboembolic events by the sample size, not the number of patients who had thromboembolic events. Therefore, the rates reported here may differ slightly from the rates reported in each study. The tests of statistical significance presented are those reported by the individual studies and are not based on the thromboembolic event rates reported in this table. ‡ P values presented are those reported by the individual studies, wherever possible. § Studies did not meet inclusion criteria for detailed review in the comparative effectiveness analyses owing to poor quality but were included in the qualitative sensitivity analyses described in the Effectiveness Review Outcomes section and the Evaluation of Harms section. (12) 67 (13) 64 (106), 79 (172), 37 (51), 4 (9) 11 ( (13) 65 (14) 18 [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] , 11 [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] 26 [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] 0.09, Ͻ0. * Thromboembolic event rates were calculated by dividing the number of thromboembolic events by the sample size, not the number of patients who had thromboembolic events. Therefore, the rates reported here may differ slightly from those reported in each study. The tests of statistical significance presented are those reported by the individual studies and are not based on the thromboembolic event rates reported in this table.
† P values presented are those reported by the individual studies. ‡ Diprose et al (34) excluded 1 patient who violated the study protocol after randomization. This patient was not evaluated for mortality or thromboembolic events. §
Median.
The hospital mortality rates at 6 mo were 0.583 in the rFVIIa group and 0.417 in the usual care group. ¶ Studies did not meet inclusion criteria for detailed review in the comparative effectiveness analyses owing to poor quality but were included in the qualitative sensitivity analyses described in the Effectiveness Review Outcomes section and the Evaluation of Harms section. * P values presented are those reported by the individual studies. † Thromboembolic event rates were calculated by dividing the number of thromboembolic events by the sample size, not the number of patients who had thromboembolic events. Therefore, the rates reported here may differ slightly from those reported in each study. The tests of statistical significance presented are those reported by the individual studies and are not based on the thromboembolic event rates reported in this table. ‡ This study generated odds ratios for survival by using a multivariate model, which included independent predictors of in-hospital survival (baseline pH, platelet count, age, head injury, and transfusion during the resuscitation period) as covariates. Before modeling, the unadjusted in-hospital mortality rates were 0.500 in the rFVIIa group and 0.485 in the usual care group. In the multivariate models, rFVIIa was shown to have no significant effect on in-hospital survival (odds ratio, 2.5 [95% CI, 0.8 -7.6]) but to improve 24-h survival (odds ratio, 3.4 [CI, 1.2-9.8]). § Nascimento et al (109) is an extension of Rizoli et al (49) but with more patients. It also reports data on thromboembolic events not reported in the original publication.
Wade et al (51) is an extension of Spinella et al (110) using patient data from the U.S. Joint Theater Trauma Registry but only reports on total mortality (not thromboembolic event or ARDS rates) for the propensity-matched group of patients (n ϭ 266), so that the earlier data from Spinella et al (110) are used for the thromboembolic event and ARDS rates. ¶ Median.
** 24-h mortality. † † Studies did not meet inclusion criteria for detailed review in the comparative effectiveness analyses owing to poor quality but were included in the qualitative sensitivity analyses described in the Effectiveness Review Outcomes section and the Evaluation of Harms section. ‡ ‡ Dutton et al (60) has several control groups. The range of sample sizes is presented. For purposes of outcome data, rates for the most narrow sample (n ϭ 32) and most broad sample (n ϭ 449) are given, respectively. § § 28-d mortality.
Venous thromboembolic events only. ¶ ¶ The description from Woodruff et al (62) of mean rFVIIa dose may inaccurate because it reports the dose to be 9.6 mg/kg and not mcg/kg, which would be more than 1 magnitude larger than the doses reported in the body trauma RCTs or any other report of off-label rFVIIa use. * Thromboembolic event rates were calculated by dividing the number of thromboembolic events by the sample size not the number of patients who had thromboembolic events. Therefore, the rates reported here may differ slightly from those reported in each study. The tests of statistical significance presented are those reported by the individual studies and are not based on the thromboembolic event rates reported in this table.
† P values presented are those reported by the individual studies. ‡ Odds ratio and 95% CI. § Data are for patients with isolated traumatic brain injury only. Studies did not meet inclusion criteria for detailed review in the comparative effectiveness analyses owing to poor quality but were included in the qualitative analyses described in the Effectiveness Review Outcomes section and the Evaluation of Harms section. ¶ Reported only for both groups combined: 50 y (SD, 21).
**
Odds ratio and 95% CI for rFVIIa group vs. usual care group. Multivariate analyses demonstrate higher adjusted odds ratio of cerebral infarction with rFVIIa treatment.
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